Serum WFA+-M2BP levels for evaluation of early stages of liver fibrosis in patients with chronic hepatitis B virus infection-Reference-Cited by-同舟云学术

Serum WFA+-M2BP levels for evaluation of early stages of liver fibrosis in patients with chronic hepatitis B virus infection

Published:2016-07-12 Issue:1 Volume:37 Page:35-44
ISSN:1478-3223
Container-title:Liver International
language:en
Short-container-title:Liver Int

Author:

Zou Xia¹²³⁴,Zhu Ming-Yu¹,Yu De-Min¹,Li Wei²,Zhang Dong-Hua¹,Lu Fei-Jie²,Gong Qi-Ming¹,Liu Feng²,Jiang Jie-Hong¹,Zheng Min-Hua³,Kuno Atsushi⁴⁵,Narimatsu Hisashi⁴⁵,Zhang Yan²⁴⁶,Zhang Xin-Xin¹⁷

Affiliation:

1. Department of Infectious Diseases; Ruijin Hospital; Shanghai Jiao Tong University School of Medicine; Shanghai China

2. Ministry of Education Key Laboratory of Systems Biomedicine; Shanghai Center for Systems Biomedicine; Shanghai Jiao Tong University; Shanghai China

3. Department of Surgery; Ruijin Hospital; Shanghai Jiao Tong University School of Medicine; Shanghai China

4. SCSB (China)-AIST (Japan) Joint Medical Glycomics Laboratory; Shanghai China

5. Research Center for Medical Glycoscience; National Institute of Advanced Industrial Science and Technology (AIST); Tsukuba Ibaraki Japan

6. Collaborative Innovation Center of Systems Biomedicine; Shanghai China

7. Translational Medicine Research Center; Ruijin Hospital North; Shanghai Jiao Tong University School of Medicine; Shanghai China

Funder

National Basic Research Program of China

National High Technology Research and Development Program of China

International Science & Technology Cooperation Program of China

Shanghai International Science & Technology Cooperation Program of China

China Postdoctoral Science Foundation

Major National Projects for Infectious Diseases

Publisher

Wiley

Subject

Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/liv.13188/fullpdf

Reference37 articles.

1. Antiviral therapy for chronic hepatitis B in China;Zheng;Med Microbiol Immunol,2015

2. World Health Organization Hepatitis B http://www.who.int/mediacentre/factsheets/fs204/en/

3. Hepatitis B virus infection-natural history and clinical consequences;Ganem;N Engl J Med,2004

4. Clinical evidence for the regression of liver fibrosis;Ellis;J Hepatol,2012

5. Complications following percutaneous liver biopsy. A multicentre retrospective study on 68,276 biopsies;Piccinino;J Hepatol,1986

Cited by 66 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Revisiting Mac-2-Binding Protein Glycosylation Isomer (M2BPGi) for Diagnosing High-Risk Liver Fibrosis in Chronic Hepatitis B Patients: A Stepwise Diagnostic Analysis;F1000Research;2024-07-12

2. Comparison of serum WFA⁺‐M2BP, FIB‐4, and APRI for cirrhosis and esophageal varices prediction in hepatoma patients;Advances in Digestive Medicine;2024-06-05

3. MicroRNA-223-3p levels in serum-derived extracellular vesicles predict regression of M2BPGi-based liver fibrosis after hepatitis C virus eradication by direct-acting antiviral agents;Journal of Gastroenterology;2024-05-13

4. Revisiting Mac-2-Binding Protein Glycosylation Isomer (M2BPGi) for Diagnosing High-Risk Liver Fibrosis: A Stepwise Diagnostic Analysis;F1000Research;2024-04-16

5. Accuracy of blood-based biomarkers for staging liver fibrosis in chronic liver disease: A systematic review supporting the AASLD Practice Guideline;Hepatology;2024-03-15